{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:37:34Z","timestamp":1760985454380},"reference-count":11,"publisher":"Cambridge University Press (CUP)","issue":"S1","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"unspecified","delay-in-days":11552,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[1984,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Effective control of parkinsonian symptoms can be achieved in a substantial number of patients by the judicious use of dopaminergic agents. To a considerable extent these drugs produce optimal therapeutic effects during the first 3\u20135 years of their use. Subsequently, efficacy diminishes with reemergence of parkinsonian symptoms as well as a number of untoward responses. The nature, frequency and mechanisms underlying the limitations of long term use of presently available anti-parkinson agents are discussed in this presentation.<\/jats:p>","DOI":"10.1017\/s0317167100046394","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T07:36:04Z","timestamp":1469691364000},"page":"191-194","source":"Crossref","is-referenced-by-count":15,"title":["Limitations of Long Term Use of Antiparkinson Drugs"],"prefix":"10.1017","volume":"11","author":[{"given":"Melvin D.","family":"Yahr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"S0317167100046394_ref724","first-page":"145","author":"Stern","year":"1981"},{"key":"S0317167100046394_ref721","doi-asserted-by":"publisher","DOI":"10.1038\/273059a0"},{"key":"S0317167100046394_ref727","doi-asserted-by":"crossref","unstructured":"Yahr MD (1977) Long-term levodopa in Parkinson\u2019s disease. Lancet: 986\u2013987.","DOI":"10.1016\/S0140-6736(77)92153-5"},{"key":"S0317167100046394_ref719","first-page":"444","author":"Diamond","year":"1975"},{"key":"S0317167100046394_ref723","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1981.00510060041004"},{"key":"S0317167100046394_ref728","doi-asserted-by":"publisher","DOI":"10.1159\/000114756"},{"key":"S0317167100046394_ref718","unstructured":"Bauer RB , Stevens C , Reveno WS , Rosenbaum H (1980) L-Dopa treatment of Parkinson\u2019s Disease: A ten-year follow-up study. J. Amer. Geriat. Soc. 322\u2013326."},{"key":"S0317167100046394_ref726","doi-asserted-by":"crossref","unstructured":"Yahr MD , Clough CG , Bergmann KJ (1982) Cholinergic and dopaminergic mechanisms in Parkinson\u2019s disease after long term levodopa administration. Lancet: 709\u2013710.","DOI":"10.1016\/S0140-6736(82)90728-0"},{"key":"S0317167100046394_ref720","first-page":"41","author":"Hornykiewicz","year":"1982"},{"key":"S0317167100046394_ref722","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91146-1"},{"key":"S0317167100046394_ref725","first-page":"435","volume-title":"Advances in Parkinsonism","author":"Yahr","year":"1975"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167100046394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T17:35:47Z","timestamp":1558632947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167100046394\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,2]]},"references-count":11,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1984,2]]}},"alternative-id":["S0317167100046394"],"URL":"https:\/\/doi.org\/10.1017\/s0317167100046394","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,2]]}}}